-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $33 Price Target

Benzinga·01/23/2026 12:52:55
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $33 price target.